GPRC5D-Targeted CAR T Cells for Myeloma
Sham Mailankody(Memorial Sloan Kettering Cancer Center), Eric L. Smith(Dana-Farber Cancer Institute), Kinga Hosszu, Terence J. Purdon(Memorial Sloan Kettering Cancer Center), Malin Hultcrantz(United States Fish and Wildlife Service), Tasmin Farzana(United States Fish and Wildlife Service), Gunjan L. Shah(Cornell University), Urvi A. Shah(United States Fish and Wildlife Service), Briana Cadzin(United States Fish and Wildlife Service), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), Jessica Wilcox(United States Fish and Wildlife Service), Filiz Şen(United States Fish and Wildlife Service), Jonathan Landa(United States Fish and Wildlife Service), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Claudia Diamonte(Memorial Sloan Kettering Cancer Center), Devanjan Sikder(The University of Texas Southwestern Medical Center), Isabelle Rivière(Memorial Sloan Kettering Cancer Center), Bianca Santomasso(Georgetown University), Xiuyan Wang(Jilin Normal University), Sean M. Devlin(Memorial Sloan Kettering Cancer Center), Elizabeth J. Carstens(United States Fish and Wildlife Service), Devin McAvoy(United States Fish and Wildlife Service), Hani Hassoun(Memorial Sloan Kettering Cancer Center), Neha Korde(United States Fish and Wildlife Service), Brigitte Sénéchal(Memorial Sloan Kettering Cancer Center), Jae H. Park(University of Tennessee at Knoxville), Renier J. Brentjens(Roswell Park Comprehensive Cancer Center), Lisa Fitzgerald(United States Fish and Wildlife Service), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Romany Auclair(United States Fish and Wildlife Service), Mikhail Roshal(Memorial Sloan Kettering Cancer Center), Ola Landgren(University of Miami Health System), Carlyn Tan(United States Fish and Wildlife Service), Karthik Nath(United States Fish and Wildlife Service), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 383
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k